Milad ibrahim

Dr. Milad ibrahim

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
KMKelsey Monson
Kelsey Monson
RFRobert Ferguson
Robert Ferguson
JHJoanna E. Handzlik
Joanna E. Handzlik
LMLeah Morales
Leah Morales
JXJiahan Xiong
Jiahan Xiong
TKTomas Kirchhoff
Tomas Kirchhoff
Response to immune checkpoint inhibitors (ICIs) in metastatic melanoma (MM) varies among patients, and current baseline biomarkers predicting treatment outcomes are limited. As mitochondrial (MT) metabolism has emerged as an important regulator of host immune function, we explored the association of host MT genetics (MT haplogroups) with ICI efficacy in 1,225 ICI-treated patients with MM from the clinical trial CheckMate-067 and the International Germline Immuno-Oncology Melanoma Consortium. We discovered and validated significant associations of MT haplogroup T (HG-T) with resistance to anti-programmed cell death protein-1-based ICI (both single-agent and combination) and have shown that HG-T is independent from established tumor predictors. We also found that patients belonging to HG-T exhibit a unique nivolumab-resistant baseline peripheral CD8+ T cell repertoire compared to other MT haplogroups, providing, to our knowledge, the first link between MT inheritance, host immunity and ICI resistance. The study proposes a host blood-based biomarker with stand-alone clinical value predicting ICI efficacy and points to an ICI-resistance mechanism associated with MT metabolism, with clinical relevance in immuno-oncology.

18 August 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
George JourGeorge Jour
George Jour
IIIrineu Illa-Bochaca
Irineu Illa-Bochaca
MIMilad ibrahim
Milad ibrahim
DDDouglas Donnelly
Douglas Donnelly
KZKelsey Zhu
Kelsey Zhu
IOIman Osman
Iman Osman
There is currently no targeted therapy to treat NF1-mutant melanomas. In this study, we compared the genomic and transcriptomic signatures of NF1-mutant and NF1 wild-type melanoma to reveal potential treatment targets for this subset of patients. Genomic alterations were verified using qPCR, and differentially expressed genes were independently validated using The Cancer Genome Atlas data and immunohistochemistry. Digital spatial profiling with multiplex immunohistochemistry and immunofluorescence were used to validate the signatures. The efficacy of combinational regimens driven by these signatures was tested through in vitro assays using low-passage cell lines. Pathogenic NF1 mutations were identified in 27% of cases. NF1-mutant melanoma expressed higher proliferative markers MK167 and CDC20 than NF1 wild-type (P = 0.008), which was independently validated both in The Cancer Genome Atlas dataset (P = 0.01, P = 0.03) and with immunohistochemistry (P = 0.013, P = 0.036), respectively. Digital spatial profiling analysis showed upregulation of LY6E within the tumor cells (false discovery rate < 0.01, log2 fold change > 1), confirmed with multiplex immunofluorescence showing colocalization of LY6E in melanoma cells. The combination of MAPK/extracellular signal‒regulated kinase kinase and CDC20 coinhibition induced both cytotoxic and cytostatic effects, decreasing CDC20 expression in multiple NF1-mutant cell lines. In conclusion, NF1-mutant melanoma is associated with a distinct genomic and transcriptomic profile. Our data support investigating CDC20 inhibition with MAPK pathway inhibitors as a targeted regimen in this melanoma subtype.

14 July 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
FFFaisal Fa’aK
Faisal Fa’aK
NCNicolas Coudray
Nicolas Coudray
George JourGeorge Jour
George Jour
MIMilad ibrahim
Milad ibrahim
IIIrineu Illa-Bochaca
Irineu Illa-Bochaca
IOIman Osman
Iman Osman
Purpose: Cancer treatment has been revolutionized by immune checkpoint inhibitors (ICI). However, a subset of patients do not respond and/or they experience significant adverse events. Attempts to integrate reliable biomarkers of ICI response as part of standard care have been hampered by limited generalizability. We previously reported our supervised machine learning (ML) model in a retrospective cohort of metastatic melanoma. Experimental Design: In this study, we expanded our testing to include larger cohorts of patients with melanoma accrued at several sites, including patients enrolled in clinical trials in both adjuvant and metastatic settings. We examined pretreatment hematoxylin and eosin slides from 639 patients with stage III/IV melanoma treated with ICIs [anti–cytotoxic T-lymphocyte–associated protein 4 (n = 212), anti-programmed death 1 (n = 271), or the combination (n = 156)]. We tested the generalizability of our supervised ML algorithm to predict response to ICIs in the metastatic melanoma cohort and then developed a self-supervised ML model to identify the histologic morphologies associated with patients’ survival following ICI use in adjuvant and metastatic melanoma cohorts. Results: We predicted the response to ICI treatment with an AUC of 0.72. The deep convolutional neural network classified patients into high and low risk based on their likelihood of progression-free survival (P < 0.0001). We uncovered a novel association of specific histomorphologic tumor features—epithelioid histology and a low tumor–stroma ratio—with survival following ICI treatment. Conclusions: Our data support the generalizability of our developed ML algorithm in predicting response to ICI treatment in patients with metastatic unresectable melanoma. We also showed, for the first time, tumor features associated with patients’ overall survival.

10 June 2025 in Cancer Research
Verified
Journal Article
Open access
MIMilad ibrahim
Milad ibrahim
IIIrineu Illa-Bochaca
Irineu Illa-Bochaca
George JourGeorge Jour
George Jour
EMEleazar Vega-Saenz de Miera
Eleazar Vega-Saenz de Miera
JFJoseph Fracasso
Joseph Fracasso
MSMarkus Schober
Markus Schober
Targeted therapies and immunotherapy have improved treatment outcomes for many patients with melanoma. However, patients whose melanomas harbor driver mutations in the neurofibromin 1 (NF1) tumor suppressor gene often lack effective targeted treatment options when their tumors do not respond to immunotherapy. In this study, we utilized patient-derived short-term cultures and multiomics approaches to identify molecular features that could inform the development of therapies for patients with NF1-mutant (NF1Mut) melanoma. Differential gene expression analysis revealed that EGFR is highly expressed and active in NF1Mut melanoma cells, in which it hyperactivates ERK and AKT, leading to increased tumor cell proliferation, survival, and growth. In contrast, genetic or pharmacologic inhibition of EGFR hindered cell proliferation and survival and suppressed tumor growth in patient-derived NF1Mut melanoma models but not in NF1 wild-type models. These results reveal a connection between NF1 loss and increased EGFR expression that is critical for the survival and growth of NF1Mut melanoma cells in patient-derived culture and xenograft models, irrespective of their BRAF and NRAS mutation status. Significance: NF1 mutant melanomas rely on EGFR activation and can be effectively treated with the EGFR inhibitors cetuximab or afatinib, supporting further testing in clinical trials.

19 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MIMilad ibrahim
Milad ibrahim
IIIrineu Illa-Bochaca
Irineu Illa-Bochaca
FFFaisal Fa’ak
Faisal Fa’ak
KMKelsey Monson
Kelsey Monson
RFRobert Ferguson
Robert Ferguson
IOIman Osman
Iman Osman
Background: We previously reported a higher incidence of a pathogenic germline variant in the kinase insert domain receptor (KDR) in melanoma patients compared to the general population. Here, we dissect the impact of this genotype on melanoma tumor growth kinetics, tumor phenotype, and response to treatment with immune checkpoint inhibitors (ICIs) or targeted therapy. Methods: The KDR genotype was determined and the associations between the KDR Q472H variant (KDR-Var), angiogenesis, tumor immunophenotype, and response to MAPK inhibition or ICI treatment were examined. Melanoma B16 cell lines were transfected with KDR-Var or KDR wild type (KDR-WT), and the differences in tumor kinetics were evaluated. We also examined the impact of KDR-Var on the response of melanoma cells to a combination of VEGFR inhibition with MAPKi. Results: We identified the KDR-Var genotype in 81/489 (37%) patients, and it was associated with a more angiogenic (p = 0.003) and immune-suppressive tumor phenotype. KDR-Var was also associated with decreased PFS to MAPKi (p = 0.022) and a trend with worse PFS to anti-PD1 therapy (p = 0.06). KDR-Var B16 murine models had increased average tumor volume (p = 0.0027) and decreased CD45 tumor-infiltrating lymphocytes (p = 0.0282). The anti-VEGFR treatment Lenvatinib reduced the tumor size of KDR-Var murine tumors (p = 0.0159), and KDR-Var cells showed synergistic cytotoxicity to the combination of dabrafenib and lenvatinib. Conclusions: Our data demonstrate a role of germline KDR-Var in modulating melanoma behavior, including response to treatment. Our data also suggest that anti-angiogenic therapy might be beneficial in patients harboring this genotype, which needs to be tested in clinical trials.

2 June 2026 in FEBS Open Bio
Verified
Journal Article
Open access
MIMilad ibrahim
Milad ibrahim
Marco CorazzariMarco Corazzari
Marco Corazzari
IOIman Osman
Iman Osman
JAJane Armstrong
Jane Armstrong
NCNoel Carter
Noel Carter
The protein activating molecule in Beclin1‐regulated autophagy1 (AMBRA1), discovered in 2007, is crucial for autophagy and plays roles in nervous system development, cell survival, and proliferation. Here, we investigated AMBRA1's involvement in various cellular processes using a systems‐based “omics” approach, focusing on melanoma. Transcriptomic analysis of AMBRA1 overexpression or knock‐down was shown to result in significant dysregulation of several transcripts. We identified several novel roles for AMBRA1 in a range of cellular pathways including cancer signaling pathways such as MAPK, angiogenesis, tissue growth factor signaling, axon guidance, and Wnt signaling. Furthermore, using yeast two‐hybrid assays, we identified novel binding partners which provide evidence of new roles for AMBRA1 in different cellular processes. Ultimately, we conclude that AMBRA1 loss upregulates metastatic genes/proteins highlighting AMBRA1 as a tumor suppressor gene in melanoma.